21st.BIO Funding: How Much Did They Raise & Key Investors

How Much Did 21st.BIO Raise?
Funding & Key Investors

21st.BIO has successfully secured a major strategic investment, marking a pivotal milestone in its corporate trajectory. With a total funding amount reaching $96.9M, the company is well-positioned to accelerate its mission within the industrial biotechnology sector. This recent capital injection of $96.9M underscores the market confidence in the firm's proprietary platform technology, which is designed to streamline the transition from laboratory-scale research to high-volume commercial manufacturing.

The infusion of resources serves as a catalyst for 21st.BIO to expand its operational footprint and enhance its strain development capabilities. By leveraging this financial backing, the company aims to solidify its position as a critical infrastructure provider for businesses navigating the complexities of biological production, ensuring that sustainable and cost-effective manufacturing becomes the industry standard.

What is 21st.BIO?

21st.BIO

Business Services

Research & Development

Founded in 2020 and headquartered in Virum, Denmark, 21st.BIO operates at the intersection of synthetic biology and industrial manufacturing. The company specializes in optimizing expression platforms for the large-scale production of complex molecules. By utilizing a sophisticated methodology that tests various biological hosts—including fungi, yeast, and bacteria—21st.BIO identifies the most efficient production pathways for its clients. Their comprehensive strain bank and optimization expertise allow partners to achieve commercially viable yields, effectively bridging the gap between innovative molecular discovery and mass-market availability. This service-oriented model is essential for companies seeking to scale production without compromising on quality or economic feasibility.

How much funding has 21st.BIO raised?

21st.BIO has raised a total of $96.9M across 1 funding round:

2021

Private Equity

$96.9M

Private Equity (2021): $96.9M with participation from Novo Holdings

Key Investors in 21st.BIO

Novo Holdings

Novo Holdings is a prominent Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term investments in life science companies.

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for 21st.BIO?

Looking ahead, 21st.BIO is poised to leverage its recent capital to deepen its technological moat and broaden its client base across the global biotech landscape. The strategic focus will likely center on scaling its internal strain development infrastructure and refining its proprietary expression platforms to accommodate an increasingly diverse range of molecular targets. As the demand for bio-based manufacturing solutions continues to rise, 21st.BIO is strategically positioned to capture significant market share by providing the foundational tools necessary for the next generation of industrial production. Future growth will be driven by continued investment in R&D and the expansion of its collaborative network, ensuring that the company remains at the forefront of the bio-industrial revolution.

See full 21st.BIO company page

See More Financial Insights